Results 51 to 60 of about 3,514 (173)

Osteitis Fibrosa Cystica: An Unusual Cause of Left‐Sided Chest Pain

Case Reports in Nephrology, Volume 2026, Issue 1, 2026.
We report a case of osteitis fibrosa cystica resulting from secondary hyperparathyroidism in a 21‐year‐old male patient with end‐stage renal disease. The patient presented with persistent, moderate chest pain localized to the left fifth and sixth ribs for eight months. A chest X‐ray revealed well‐defined, expansile lytic lesions in these ribs.
Raahima Habib, Maha Anjum, Ayesha Mahmood, Nabiha Rizvi, Poulami Jha   +4 more
wiley   +1 more source

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2014
In the present study, a comparative evaluation of the effects of calcium acetate, calcium carbonate, sevelamer hydrochloride and lanthanum carbonate was carried out in 120 patients with end stage kidney disease (ESKD) undergoing hemodialysis. Biochemical
Viken A Prajapati, Varsha J Galani, Pankaj R Shah   +2 more
doaj   +1 more source

Calciphylaxis Post‐Renal Transplantation: Two Cases and a Literature Review

Organ Medicine, Volume 2, Issue 4, Page 153-159, December 2025.
Calciphylaxis post‐renal transplant is a life‐threatening vasculopathy with high mortality. We report two cases managed successfully via early histopathological diagnosis and intravenous sodium thiosulfate therapy. Early diagnosis and intervention, along with renal function recovery, positively impact prognosis, highlighting the clinical relevance of ...
Luhao Liu, Rongxin Chen, Yuhe Guo, Ziqing Guo, Peng Zhang, Wei Yin, Guanghui Li, Jiali Fang, Zheng Chen   +8 more
wiley   +1 more source

A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis

International Journal of Nephrology and Renovascular Disease, 2014
Moustafa Moustafa,1 Lawrence Lehrner,2 Fahd Al-Saghir,3 Mark Smith,4 Sunita Goyal,5 Maureen Dillon,5 John Hunter,5 Randy Holmes-Farley5 1South Carolina Nephrology and Hypertension Center Inc., Orangeburg, SC, USA; 2Kidney Specialists of Southern Nevada ...
Moustafa M, Lehrner L, Al-Saghir F, Smith M, Goyal S, Dillon M, Hunter J, Holmes-Farley R   +7 more
doaj  

Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study.

PLoS ONE, 2013
p-Cresol is a by-product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria. In patients with chronic kidney disease, the accumulation of p-cresol and of its metabolite p-cresyl-sulphate causes endothelial dysfunction and ...
Bruna Guida, Mauro Cataldi, Eleonora Riccio, Lucia Grumetto, Andrea Pota, Silvio Borrelli, Andrea Memoli, Francesco Barbato, Gennaro Argentino, Giuliana Salerno, Bruno Memoli   +10 more
doaj   +1 more source

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial

, 2019
Rationale & Objective: Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers.
Ruggenenti, Piero, Perna, Annalisa, Peraro, Francesco, Remuzzi, Giuseppe, Zoccali, Carmine, Ruggiero, Barbara, Perticucci, Elena, Villa, Davide, Lecchi, Veruska, Tartaglione, Lida, Aparicio, Carolina, Tripepi, Rocco, Trillini, Matias, Rotondi, Silverio, Cozzolino, Mario, Mallamaci, Francesca, Ferrari, Silvia, Bellasi, Antonio, Kohan, Donald E., Mazzaferro, Sandro, Cannata, Antonio   +20 more
core   +2 more sources

"Fish-scales" and graft nephrectomy: unexpected findings at an unusual site [PDF]

Journal of Nephropathology, 2017
Background: Kayexalate and sevelamer are resin medications commonly used in the setting of chronic renal failure for the treatment of hyperkalemia and hyperphosphatemia respectively, are known to cause bowel ischemia, ulcerations, necrosis, pseudotumors ...
Smiley Annie George, Issam Francis
doaj   +1 more source

Single Center, Open‐Label, Randomized Crossover Trial on Drug–Drug Interactions of Levothyroxine/Magnesium‐Citrate and Levothyroxine/Magnesium‐Aspartate in Healthy Subjects—The ThyroMag Trial

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Divalent cations such as calcium and ferrous sulfate interfere with the absorption of levothyroxine due to complexing. To our knowledge, the effects of magnesium on levothyroxine absorption have never been studied. The open‐label cross‐over pharmacokinetic study was conducted in 15 healthy, euthyroid adults.
Martin Christian Attinger, Stefanie von Felten, Claudia Lourenço Rodrigues, Jan Krützfeldt, Lorenz Risch, Jérôme Bonzon   +5 more
wiley   +1 more source

Development of Deferoxamine‐Functionalized Cyclodextrin Polymer for Targeted Iron Chelation

ChemistryOpen, Volume 14, Issue 10, October 2025.
The cyclodextrin polymer is conjugated with 35 deferoxamine units and can form iron(III) complexes. The polymer exhibits significantly lower antiproliferative activity than free deferoxamine. The cyclodextrin polymer with multiple deferoxamine units may present a promising strategy for improving the efficacy of iron chelation therapies.
Roberta Panebianco, Maurizio Viale, Graziella Vecchio   +2 more
wiley   +1 more source

Chronic kidney disease in the primary care setting: A narrative review

Journal of General and Family Medicine, Volume 26, Issue 5, Page 385-393, September 2025.
Abstract Chronic kidney disease (CKD) is a growing public health concern globally, with primary care physicians (PCPs) playing a pivotal role in its early detection and management. This review explores the epidemiology, risk factors, screening strategies, and clinical manifestations of CKD within primary care settings.
Faryal Safdar, Ahsan Aslam
wiley   +1 more source